RESUMO
Very little is known about the role played by complement in vivo during Trichinella spiralis infections, although previous reports indicate that it binds readily to the surfaces of muscle stages of the parasite in vitro. In order to study the binding of complement to muscle-stage larvae in vivo, larvae were recovered from BALB-c inbred, NFR/N inbred, and Swiss white outbred mice from 20 to 95 days postinfection. The presence of C3 was examined by direct immunofluorescence and leucocyte- and erythrocyte-adherence tests. Complement was found on a few larvae from the outbred strain and only rarely on larvae from the 2 inbred strains. Histological sections prepared from inbred strains and used in immunofluorescence tests to study in situ complement activation and binding were negative. Larvae from all 3 mouse strains bound complement 100% of the time when it was added to the worms in vitro. The results indicate that extrapolation from in vitro to in vivo activation and binding of complement to T. spiralis larvae may not be valid.
Assuntos
Ativação do Complemento , Trichinella/imunologia , Triquinelose/sangue , Animais , Eritrócitos/parasitologia , Humanos , Larva , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Endogâmicos , Especificidade da Espécie , Trichinella/isolamento & purificação , Triquinelose/imunologiaRESUMO
Forty 3-month old swine were treated with immunomodulating Propionibacterium avidum KP-40 (PA) and/or vaccinated with a formalin-inactivated mixture of serotypes 1, 3, 5 and 9 of Haemophilus pleuropneumoniae (Pleurovac). Three weeks after revaccination all animals were inoculated with viable single serotypes of Haemophilus pleuropneumoniae. The IgG antibodies induced by vaccination agglutinated all serotypes of Haemophilus pleuropneumoniae, except for serotype 5. Antibody titers were not influenced by the application of PA together with the vaccine. Infection of vaccinated piglets resulted in the development of pleuropneumonia in 8 out of 10 animals, while vaccination together with application of PA lowered the morbidity rate to 1 out of 10 (p < 0.05). The usefulness of a PA prophylaxis was also demonstrated in non-vaccinated piglets infected with Haemophilus pleuropneumoniae. Because of the considerable variability of strains and serotypes of Haemophilus pleuropneumoniae and the generally low prophylactic potency of pleuropneumonia vaccines it is concluded that long-lasting enhancement of non-specific antiinfective resistance caused by PA may lower the risk of endemic infections in vaccinated piglets.
Assuntos
Actinobacillus pleuropneumoniae/imunologia , Adjuvantes Imunológicos/administração & dosagem , Vacinas Bacterianas/administração & dosagem , Propionibacterium/imunologia , Infecções por Actinobacillus/prevenção & controle , Infecções por Actinobacillus/veterinária , Actinobacillus pleuropneumoniae/classificação , Actinobacillus pleuropneumoniae/patogenicidade , Animais , Anticorpos Antibacterianos/biossíntese , Estudos de Avaliação como Assunto , Imunoglobulina G/biossíntese , Sorotipagem , Suínos , Doenças dos Suínos/prevenção & controle , Vacinas de Produtos Inativados/administração & dosagem , VirulênciaRESUMO
Fifty 4-month old piglets were treated with immunomodulating Propionibacterium avidum KP-40 (PA) and/or immunized with live attenuated Erysipelothrix rhusiopathiae vaccine (Orvac). Four weeks after vaccination all animals were inoculated with viable Erysipelothrix rhusipathiae. The vaccine induced the appearance of high titers of specific IgG antibodies with peak values (1:115-1:200) three weeks after immunization. Administration of PA together with the vaccine did not influence antibody titers. Analysis of the course of experimental erysipelas infection in vaccinated and/or PA-treated swine revealed the prophylactic and beneficial effects of PA. PA-treated animals showed a significantly lower lethality rate than untreated controls and the course of the disease was considerably milder, with a shorter period of fever and a faster recovery. Vaccination provided good protection of swine against the development of erysipelas and therefore, the only significant difference in animals treated with PA applied together with the vaccine was a higher gain of body mass after infection.
Assuntos
Adjuvantes Imunológicos/administração & dosagem , Vacinas Bacterianas/administração & dosagem , Erysipelothrix/imunologia , Propionibacterium/imunologia , Animais , Anticorpos Antibacterianos/biossíntese , Erysipelothrix/patogenicidade , Infecções por Erysipelothrix/prevenção & controle , Imunoglobulina G/biossíntese , Suínos , Doenças dos Suínos/prevenção & controle , Vacinas Atenuadas/administração & dosagem , VirulênciaRESUMO
Impregnated Swiss mice were irradiated 2 h daily on days 1-18 of gestation in nonthermal (1 or 10 mW/cm2) or thermogenic (40 mW/cm2) 2,450-MHz microwave (MW) fields. On the 19th day of pregnancy all dams were killed to check the number of resorptions. Living fetuses were isolated, weighed and checked for the presence of macroscopically visible malformations of skeleton and cleft palate (CP) and/or lip (CLP). Some of the pregnant mice in each group were injected intraperitoneally on the 9th day of gestation with 10 mg/kg of cytosine arabinoside (ara-C), a well-known teratogen resulting under the above conditions in the appearance of about 15% (42 of 354) of resorbed implantation points and the development of CP or CLP in about 30% (96 of 312) of fetuses. Exposure to nonthermal MW fields during pregnancy did not lead to resorptions or detectable malformations; however, the body mass of 19-day fetuses was significantly lower than in sham-irradiated controls. MW hyperthermia (40 mW/cm2) applied during pregnancy led to an increased number of resorptions - about 25% (37 of 157) compared to 2% (6 of 306) in controls. Significant enhancement of the teratogenic potency of ara-C was observed after combined exposure to both ara-C and MWs during pregnancy. In dams treated with ara-C alone about 20% (62 of 358) resorptions and about 30% (91 of 296) fetuses with CL or CLP were found; additional exposure in MW fields (10 mW/cm2), not resulting per se in resorptions or detectable malformations, increased the numbers to 45% (213 of 448) of resorptions and to 70% (167 of 235) fetuses with CL or CLP.+
Assuntos
Anormalidades Induzidas por Medicamentos/etiologia , Anormalidades Induzidas por Radiação/etiologia , Citarabina/toxicidade , Micro-Ondas/efeitos adversos , Animais , Peso Corporal/efeitos dos fármacos , Peso Corporal/efeitos da radiação , Feminino , Morte Fetal/etiologia , Gravidez , RatosRESUMO
Studies on lymphocyte subsets, mitogen transformation and NK cytotoxicity of blood mononuclear cells (BMNC) were performed in 30 patients who received transrectal microwave hyperthermia (TRHT) of the prostate. Of the 30 patients, 15 had advanced adenocarcinoma of the prostate (CAP) and 15 had severely symptomatic benign prostatic hyperplasia (BPH). Local TRHT was given twice a week for a total of six sessions. The treatments were administered at 2450 MHz or 434 MHz using a water-cooled rectal applicator. Each TRHT session lasted for 30 min at steady-state temperature controlled on the rectal mucosa at 45 degrees C. Studies of immune reactions were performed before TRHT, at the completion of six TRHT sessions, and at 1, 2, 4, and 6 months from therapy. Identical studies at the same time-interval were performed in 30 healthy male volunteers. In the 15 CAP patients the results of the immune studies obtained before TRHT, including CD4+/CD8+ ratio, PHA and Con-A transformation indices were significantly lower (p less than 0.01) than in the 15 BPH patients and in the 30 normal volunteers. The 15 BPH patients and the 30 normal volunteers all had immune parameters within the normal limits. Following the administration of TRHT in the 15 CAP patients, a transient significant (p less than 0.01) stimulation of the tested cell-mediated immune parameters was observed when compared with the pretreatment values. The peak effect of this stimulation was noted at 2 months with a subsequent decrease. In the 15 BPH patients a lesser degree of immune stimulation was noted. As expected there was no substantial change in the measured cell-mediated immune parameters in the 30 normal volunteers. A significant increase of NK cytotoxic activity was noted following TRHT in CAP patients when compared with the pretreatment results. This activity reached 120-130% of the individual initial values, being significant at p less than 0.01. The finding of transient stimulation of cell-mediated immune reaction, following local hyperthermia in patients with CAP, may be of some clinical relevance and of clinical importance. Additional studies are being formulated to confirm these interesting findings.
Assuntos
Adenocarcinoma/terapia , Hipertermia Induzida , Imunidade Celular , Hiperplasia Prostática/terapia , Neoplasias da Próstata/terapia , Adenocarcinoma/imunologia , Adulto , Idoso , Citotoxicidade Imunológica , Humanos , Células Matadoras Naturais/imunologia , Ativação Linfocitária , Masculino , Micro-Ondas/uso terapêutico , Hiperplasia Prostática/imunologia , Neoplasias da Próstata/imunologia , Subpopulações de Linfócitos T/imunologiaRESUMO
Fifteen patients with advanced (T3-4, Nx-2, M0-1) prostatic adenocarcinoma were treated with local microwave hyperthermia (LMwH) applied as the sole method of therapy (automatically controlled set generating 2,450 MHz microwaves with intrarectal applicator). All patients were monitored with a battery of tests, including USG image and volumetry of prostate, bone scintigraphy, serum alkaline phosphatase and serum level of PAP. LMwH sessions were well tolerated and did not cause pain except a moderate sensation of heating in the pelvic region. 8 of these 15 patients responded to the therapy (3x complete remission and 5x partial remission). Involution of the prostatic tumor in responders was accompanied by improvement of the general clinical and urological state. In two responders bone metastases, documented scintigraphically before therapy, disappeared. 7 patients did not respond to LMwH, mostly patients with very large primary tumors.